Page 579 - IJB-10-3

International Journal of Bioprinting Bioprint micro breast cancer

18. Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic induced neighboring effect and enhanced drug penetration.
relevance of cancer-associated fibroblasts. Nat Rev Clin Adv Mater. 2018;30(14):e1706407.
Oncol. 2021;18(12):792–804. doi: 10.1002/adma.201706407
doi: 10.1038/s41571-021-00546-5
30. Di Cosimo S. Advancing immunotherapy for early-stage triple-
19. Weiss L, Orr FW, Honn KV. Interactions of cancer cells negative breast cancer. Lancet. 2020;396(10257):1046–1048.
with the microvasculature during metastasis. FASEB J. doi: 10.1016/S0140-6736(20)31962-0
1988;2(1):12–21.
doi: 10.1096/fasebj.2.1.3275560 31. Riley RS, June CH, Langer R, Mitchell MJ. Delivery
technologies for cancer immunotherapy. Nat Rev Drug
20. Strzyz P. Cancer biology: hypoxia as an off switch for gene Discov. 2019;18(3):175–196.
expression. Nat Rev Mol Cell Biol. 2016;17(10):610. doi: 10.1038/s41573-018-0006-z
doi: 10.1038/nrm.2016.119
32. Becker JC, Andersen MH, Schrama D, Thor Straten
21. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, P. Immune-suppressive properties of the tumor
Huang LE. HIF-1α induces cell cycle arrest by functionally microenvironment. Cancer Immunol Immunother.
counteracting Myc. EMBO J. 2004;23(9):1949–1956. 2013;62(7):1137–1148.
doi: 10.1038/sj.emboj.7600196 doi: 10.1007/s00262-013-1434-6
22. Hubbi ME, Kshitiz, Gilkes DM, et al. A Nontranscriptional 33. Wirtz D, Konstantopoulos K, Searson PC. The physics of
Role for HIF-1α as a Direct Inhibitor of DNA Replication. cancer: the role of physical interactions and mechanical
Sci Signal. 2013;6(262):ra10. forces in metastasis. Nat Rev Cancer. 2011;11(7):512–522.
doi: 10.1126/scisignal.2003417 doi: 10.1038/nrc3080
23. Zhang Y, Zhang H, Wang M, et al. Hypoxia in breast 34. Murphy PM. Chemokines and the molecular basis of cancer
cancer—scientific translation to therapeutic and diagnostic metastasis. N Engl J Med. 2001;345(11):833–835.
clinical applications. Front Oncol. 2021;11:652266. doi: 10.1056/NEJM200109133451113
doi: 10.3389/fonc.2021.652266
35. Zardavas D, Maetens M, Irrthum A, et al. The AURORA
24. Chen X, Song E. Turning foes to friends: targeting cancer- initiative for metastatic breast cancer. Br J Cancer.
associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):
99–115. 2014;111(10):1881–1887.
doi: 10.1038/s41573-018-0004-1 doi: 10.1038/bjc.2014.341
36. Haddad TC, Suman VJ, D’Assoro AB, et al. Evaluation of
25. Pepin F, Bertos N, Laferrière J, et al. Gene-expression
profiling of microdissected breast cancer microvasculature alisertib alone or combined with fulvestrant in patients
identifies distinct tumor vascular subtypes. Breast Cancer with endocrine-resistant advanced breast cancer: the Phase
Res. 2012;14(4):R120. 2 TBCRC041 randomized clinical trial. JAMA Oncol.
doi: 10.1186/bcr3246 2023;9(6):815–824.
doi: 10.1001/jamaoncol.2022.7949
26. Frentzas S, Simoneau E, Bridgeman VL, et al. Vessel co-
option mediates resistance to anti-angiogenic therapy in 37. Melichar B, Adenis A, Lockhart AC, et al. Safety and activity
liver metastases. Nat Med. 2016;22(11):1294–1302. of alisertib, an investigational aurora kinase A inhibitor,
doi: 10.1038/nm.4197 in patients with breast cancer, small-cell lung cancer,
non-small-cell lung cancer, head and neck squamous-
27. Jain RK. Lessons from multidisciplinary translational trials cell carcinoma, and gastro-oesophageal adenocarcinoma:
on anti-angiogenic therapy of cancer. Nat Rev Cancer. a five-arm phase 2 study. Lancet Oncol. 2015;16(4):
2008;8(4):309–316. 395–405.
doi: 10.1038/nrc2346 doi: 10.1016/S1470-2045(15)70051-3
28. Yu M, Tannock IF. Targeting tumor architecture to favor 38. Li JP, Yang YX, Liu QL, et al. The investigational Aurora
drug penetration: a new weapon to combat chemoresistance kinase A inhibitor alisertib (MLN8237) induces cell cycle
in pancreatic cancer? Cancer Cell. 2012;21(3):327–329. G2/M arrest, apoptosis, and autophagy via p38 MAPK and
doi: 10.1016/j.ccr.2012.03.002
Akt/mTOR signaling pathways in human breast cancer cells.
29. Wang C, Chen S, Wang Y, et al. Lipase-triggered water- Drug Des Devel Ther. 2015;9:1627–1652.
responsive “Pandora’s Box” for cancer therapy: toward doi: 10.2147/DDDT.S75378

Volume 10 Issue 3 (2024) 571 doi: 10.36922/ijb.2911